Form 8-K - Current report:
SEC Accession No. 0001549595-25-000108
Filing Date
2025-09-03
Accepted
2025-09-03 08:06:04
Documents
25
Period of Report
2025-09-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrix-20250903.htm   iXBRL 8-K 28178
2 EX-99.1 nurixinvestorpresentatio.htm EX-99.1 17636
6 nurixinvestorpresentatio001.jpg GRAPHIC 79338
7 nurixinvestorpresentatio002.jpg GRAPHIC 301657
8 nurixinvestorpresentatio003.jpg GRAPHIC 89380
9 nurixinvestorpresentatio004.jpg GRAPHIC 125554
10 nurixinvestorpresentatio005.jpg GRAPHIC 124161
11 nurixinvestorpresentatio006.jpg GRAPHIC 125071
12 nurixinvestorpresentatio007.jpg GRAPHIC 146139
13 nurixinvestorpresentatio008.jpg GRAPHIC 124918
14 nurixinvestorpresentatio009.jpg GRAPHIC 139022
15 nurixinvestorpresentatio010.jpg GRAPHIC 81008
16 nurixinvestorpresentatio011.jpg GRAPHIC 106467
17 nurixinvestorpresentatio012.jpg GRAPHIC 100655
  Complete submission text file 0001549595-25-000108.txt   2299887

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20250903.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20250903_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20250903_pre.xml EX-101.PRE 13046
27 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20250903_htm.xml XML 2824
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 251287784
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)